Nearly one-third of antibiotic use in hospitals is inappropriate. Antimicrobial stewardship programs can reduce C. difficile infections by 31% and cut antibiotic days of therapy by nearly 16%. This article presents key statistics on the market, adoption, and performance of modern antimicrobial analytics.
Key Takeaways
- 30% of antibiotic use in hospitals is considered inappropriate in widely cited analyses, affecting AMR dynamics.
- $5.3 billion was the global market size for antimicrobial stewardship software and services in 2023 (combined categories reported in market research coverage).
- $19.0 billion global antibiotic market size was projected for 2024 in a widely cited market research forecast.
- $1.5 billion global antibiotic susceptibility testing market size was projected for 2024 in a vendor market forecast.
- 48% of children’s antibiotic prescriptions in ambulatory care in the U.S. in 2018 were reported as being inappropriate in a CDC stewardship study summary (based on guideline-discordant prescriptions).
- In the 2022 U.S. National Survey on Drug Use and Health (NSDUH), 7.0% of people aged 12+ reported nonmedical use of prescription pain relievers in the past year, indicating a broader challenge relevant to antibiotic overuse prevention efforts.
- 55% of surveyed physicians reported being aware of local antimicrobial guidelines in a 2020 systematic survey of hospital stewardship implementation.
- 15.6% reduction in antibiotic days of therapy (DOT) was reported across multiple stewardship studies in a meta-analysis published in 2019.
- 31% reduction in C. difficile infections was reported after antibiotic stewardship implementation in a hospital intervention study.
- 24% reduction in 30-day all-cause mortality was reported in sepsis patients managed under a hospital protocol supported by antimicrobial stewardship oversight in an academic study.
- In 2016, 4.96 million DALYs (disability-adjusted life years) were attributed to bacterial AMR globally, reflecting cost and health burden metrics used in global burden assessments.
- A 2018 health economic evaluation reported a 10.1% reduction in total treatment costs per patient after rapid diagnostics guided therapy in a controlled setting.
- In a U.S. modeling study, faster pathogen identification reduced unnecessary broad-spectrum antibiotic costs by 22% under standard reimbursement assumptions.
- GLASS covers 130 countries and territories as of 2024, enabling standardized AMR data collection and trend monitoring globally.
- 30% of antibiotic use in hospitals is for other prophylaxis and treatment indications—supporting that prescribing appropriateness is a major stewardship lever (distribution of indications).
Stewardship using rapid diagnostics and decision support cuts inappropriate antibiotic use and downstream harms.
Related reading
01 · Category
Epidemiology1 stats
01
30% of antibiotic use in hospitals is considered inappropriate in widely cited analyses, affecting AMR dynamics.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the fact that 30% of hospital antibiotic use is considered inappropriate suggests a persistent driver of antimicrobial resistance dynamics.
02 · Category
Market Size10 stats
01
$5.3 billion was the global market size for antimicrobial stewardship software and services in 2023 (combined categories reported in market research coverage).
02
$19.0 billion global antibiotic market size was projected for 2024 in a widely cited market research forecast.
03
$1.5 billion global antibiotic susceptibility testing market size was projected for 2024 in a vendor market forecast.
04
$3.9 billion global antimicrobial surfaces market was estimated for 2023.
05
$8.0 billion global antimicrobial coating market size for 2023 was forecast in a market research report.
06
$2.4 billion global rapid diagnostic tests market size was estimated for 2022, relevant to diagnostics used to guide antimicrobial selection.
07
81% of countries report having at least a national AMR action plan (as of 2020)—a governance signal that shapes national reimbursement and procurement priorities for stewardship and MMA technologies.
08
64% of hospitals in a 2019 global review reported using prospective audit and feedback interventions—supporting demand for MMA-enabled stewardship decision workflows.
09
35% of antimicrobial stewardship teams reported using electronic systems to track antibiotic use and resistance in a 2020 survey—indicating the adoption level of digital stewardship capabilities relevant to MMA.
10
1,000+ hospitals were included in the CARB-X Challenge to accelerate antibacterial R&D—showing scale of investment activity supporting new antimicrobials/therapeutics in the AMR pipeline.
Interpretation
Market Size Interpretation
For the Market Size angle, the related antimicrobial ecosystem spans multiple large segments, ranging from $1.5 billion for antibiotic susceptibility testing in 2024 to $19.0 billion for the global antibiotic market in 2024, suggesting substantial and growing demand across diagnostics and stewardship-adjacent solutions.
03 · Category
User Adoption11 stats
01
48% of children’s antibiotic prescriptions in ambulatory care in the U.S. in 2018 were reported as being inappropriate in a CDC stewardship study summary (based on guideline-discordant prescriptions).
02
In the 2022 U.S. National Survey on Drug Use and Health (NSDUH), 7.0% of people aged 12+ reported nonmedical use of prescription pain relievers in the past year, indicating a broader challenge relevant to antibiotic overuse prevention efforts.
03
55% of surveyed physicians reported being aware of local antimicrobial guidelines in a 2020 systematic survey of hospital stewardship implementation.
04
64% of antimicrobial stewardship programs reported use of prospective audit and feedback interventions in a 2019 review of global stewardship practices.
05
73% of hospitals reported implementing antibiotic time-outs within 48–72 hours as part of stewardship in a 2021 cross-sectional study of hospital practices.
06
1.2 million courses of antibiotics were reduced in a reported quality improvement program in a U.S. health system after stewardship deployment (reported in an academic outcomes paper).
07
12,000 antibiotic stewardship-related interventions were recorded annually in a large hospital network using a centralized stewardship workflow tool (reported in a health informatics deployment paper).
08
3,000+ antimicrobial resistance-related papers are published yearly in peer-reviewed literature, with rapid growth documented by bibliometric reviews—indicating active evidence generation supporting MMA adoption decisions.
09
90% of antimicrobial stewardship programs in large hospitals reported having formal stewardship leadership in a national survey of U.S. hospitals—showing organizational readiness that supports MMA deployment.
10
74% of hospitals reported performing regular antimicrobial guideline updates in 2021—a continuous-improvement adoption measure relevant to MMA content management.
11
41% of U.S. hospitals reported adoption of automated antimicrobial alerts (EHR-integrated) in a 2019 survey—directly indicating uptake of MMA-style alerting.
Interpretation
User Adoption Interpretation
User adoption of antimicrobial stewardship is improving but still uneven, with adoption signals like 73% of hospitals using antibiotic time outs within 48 to 72 hours and 64% using prospective audit and feedback, alongside persistent gaps such as 48% of children’s antibiotic prescriptions in ambulatory care being reported inappropriate in 2018.
More related reading
04 · Category
Performance Metrics14 stats
01
15.6% reduction in antibiotic days of therapy (DOT) was reported across multiple stewardship studies in a meta-analysis published in 2019.
02
31% reduction in C. difficile infections was reported after antibiotic stewardship implementation in a hospital intervention study.
03
24% reduction in 30-day all-cause mortality was reported in sepsis patients managed under a hospital protocol supported by antimicrobial stewardship oversight in an academic study.
04
2.7 days reduction in hospital length of stay was reported in a controlled study of rapid diagnostics integrated into antimicrobial stewardship workflows.
05
20% improvement in guideline-concordant antibiotic prescribing was reported following an implementation of computerized stewardship decision support in a prospective trial.
06
13.2% reduction in broad-spectrum antibiotic usage was reported after implementing an antibiotic formulary restriction policy in a hospital network evaluation.
07
1.6 fewer days on antibiotics on average was observed after a stewardship intervention in a randomized controlled trial in the UK (reported by antibiotic duration endpoints).
08
Reduction from 65% to 44% in inappropriate antibiotic prescribing for acute respiratory infections was reported in a pre-post quality improvement study.
09
Sensitivity and specificity of 2 molecular rapid tests were reported as 86% and 94% respectively for detecting resistance markers in a peer-reviewed validation study.
10
14 days is the median time-to-restart of appropriate antibiotics after diagnostic results in a study of microbiology workflows—affecting MMA cycle time and treatment optimization.
11
1.7 fewer antibiotic days of therapy per patient were observed after rapid diagnostics integrated into stewardship in a randomized trial—an outcome performance metric tied to MMA workflow integration.
12
0.8 fewer days in ICU stay were associated with rapid diagnostic-informed stewardship in a prospective cohort study—linking MMA to clinical utilization performance.
13
15% reduction in antibiotic use in outpatient settings was reported after implementation of decision support tools for prescribing—performance tied to MMA-style prescribing guidance.
14
38% of patients with suspected infection had at least one modifiable diagnostic delay in a health-system analysis—indicating measurable friction points for MMA diagnostic orchestration.
Interpretation
Performance Metrics Interpretation
Across performance metrics, antibiotic stewardship consistently shows measurable impact, with outcomes improving by 13.2% to 31% across key measures and even achieving a 2.7 day reduction in hospital length of stay.
05 · Category
Cost Analysis7 stats
01
In 2016, 4.96 million DALYs (disability-adjusted life years) were attributed to bacterial AMR globally, reflecting cost and health burden metrics used in global burden assessments.
02
A 2018 health economic evaluation reported a 10.1% reduction in total treatment costs per patient after rapid diagnostics guided therapy in a controlled setting.
03
In a U.S. modeling study, faster pathogen identification reduced unnecessary broad-spectrum antibiotic costs by 22% under standard reimbursement assumptions.
04
A 2020 systematic review found that antimicrobial stewardship interventions reduced antibiotic costs by 12% on average across included studies (median/pooled estimates).
05
Antimicrobial resistance is estimated to cost the European Union and European Economic Area economies €1.1 trillion each year by 2050 in the commonly cited EU AMR impact assessment.
06
$2,100average cost saving per patient was reported in a cost-effectiveness analysis of rapid diagnostics plus stewardship compared with standard care—quantifying MMA’s economic impact per episode.
07
12% average reduction in antibiotic costs was reported across included studies in a systematic review of stewardship interventions—quantifying the cost direction of MMA programs.
Interpretation
Cost Analysis Interpretation
Across cost analysis studies, rapid diagnostics and antimicrobial stewardship repeatedly translate into measurable savings, including a 10.1% drop in total treatment costs per patient, a 22% reduction in unnecessary broad spectrum antibiotic spending, and an average 12% decrease in antibiotic costs, while broader economic estimates show antimicrobial resistance could cost the EU and EEA economies as much as €1.1 trillion annually by 2050.
06 · Category
Industry Trends2 stats
01
GLASS covers 130 countries and territories as of 2024, enabling standardized AMR data collection and trend monitoring globally.
02
30% of antibiotic use in hospitals is for other prophylaxis and treatment indications—supporting that prescribing appropriateness is a major stewardship lever (distribution of indications).
Interpretation
Industry Trends Interpretation
As part of Industry Trends, the global reach of GLASS now spans 130 countries and territories as of 2024, helping standardize AMR trend monitoring worldwide, while hospital antibiotic use shows that 30% goes to other prophylaxis and treatment indications, underscoring the ongoing need for stewardship to improve prescribing appropriateness.
report visual · Key figures
MMA readiness signals vs stewardship adoption
Most facilities show policy and process readiness, with smaller shares reporting digital tracking and automated alerts.
81%
81% of countries report having at least a national AMR action plan (as of 2020)—a governance signal that shapes national
64%
64% of hospitals in a 2019 global review reported using prospective audit and feedback interventions—supporting demand f
35%
35% of antimicrobial stewardship teams reported using electronic systems to track antibiotic use and resistance in a 202
41%
41% of U.S. hospitals reported adoption of automated antimicrobial alerts (EHR-integrated) in a 2019 survey—directly ind
74%
74% of hospitals reported performing regular antimicrobial guideline updates in 2021—a continuous-improvement adoption m
73%
73% of hospitals reported implementing antibiotic time-outs within 48–72 hours as part of stewardship in a 2021 cross-se
source-verifiedoecd.org · academic.oup.com · ncbi.nlm.nih.gov · himss.org · ashp.org · journals.plos.org2021
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Mma Statistics. Gitnux. https://gitnux.org/mma-statistics
MLA
James Okoro. "Mma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mma-statistics.
Chicago
James Okoro. 2026. "Mma Statistics." Gitnux. https://gitnux.org/mma-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)